VANCOUVER, BC / ACCESSWIRE / October 3, 2019 / Isodiol International Inc. (CSE:ISOL)(OTCQB:ISOLF)(FSE:LB6B.F) (the “Company” or “Isodiol”), announces the appointment of Andrew Alvis to serve as the Company’s President.
Mr. Alvis has diverse experience in all aspects of leadership, operational efficiency and revenue growth. He possesses a background that spans across multiple industries, with international relationship experience and an overall vast knowledge of foreign finance. Andrew held the position of Senior Finance Executive at Bank of America where he managed all accounting and finance system impacts for each acquisition as well as implementing strategies across mortgage servicing platforms to accommodate home loan delinquencies driven by the financial crisis of 2008.
In addition, Andrew Alvis was also Chief of Operations for the McDonald’s Channel, working as the central point of contact for all European investor funding, ultimately growing his relationships in Germany, Russia, Australia and Great Britain. In his time as Chief of Operations, Andrew spearheaded the development, communication and implementation of successful growth strategies where he restructured the company and eventually returned it to profitability. Through this restructuring the company realized a 50% increase in sales revenue. Furthermore, Mr. Alvis was the Data Strategy Executive at Toyota Financial Services, where he actively designed and implemented data strategies to enable secure access to trusted data, which allowed the company to make valuable business decisions while mitigating risk.
“Mr. Alvis brings great experience in different industries and has demonstrated his leadership skills, resilience and business acumen in his many successful endeavors” said CEO of Isodiol, Marcos Agramont. “Isodiol looks forward to leveraging his experiences and international relationships to help Isodiol continue to establish operations across the globe”
Follow Our Corporate Updates On Facebook at www.facebook.com/IsodiolInternationalInc/, on Twitter @Isodiolintlinc, and on Instagram @isodiol.
About Isodiol International Inc.
Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based Consumer Packaged Goods (CPG) and solutions. Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
604-409-4409
MEDIA CONTACT:
Christopher Hussey
media@isodiol.com
The CSE has not reviewed, approved or disapproved the content of this press release.
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, proposed arrangement with creditors, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.
SOURCE: Isodiol International
View source version on accesswire.com:
https://www.accesswire.com/561758/Isodiol-International-Inc-Announces-Appointment-of-Andrew-Alvis-as-President
HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…
This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…
Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…
SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…